Compare iShares MSCI Germany (DAX) (EWG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Germany (DAX) trades at $41.98 (market cap $1.44B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and iShares MSCI Germany (DAX) is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWG | RXRX | |
|---|---|---|
Market Cap | $1.44B | $2.31B |
Volume | 1,258,794 | 40,478,768 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $6.79 |
52-Week Low | $38.08 | $2.84 |
Typical Hold Time | 56 Days | 22 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% today amid bearish technical signals with 19 sell indicators versus 1 buy. The stock faces resistance at $41 with support at $40, while European market sentiment remains cautious due to ECB rate hike expectations and energy price pressures. Key financial ratios are unavailable in the current dataset.
The outlook remains cautious with technical indicators signaling bearish momentum and European macroeconomic headwinds from potential ECB tightening. Investment opportunities depend on resolution of energy inflation concerns, while risks include further rate hikes and deteriorating eurozone business confidence.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
